Tempus AI (NASDAQ:TEM) Trading Up 6.7% - Still a Buy?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s share price rose 6.7% on Friday . The company traded as high as $62.15 and last traded at $61.05. Approximately 9,209,341 shares were traded during trading, a decline of 6% from the average daily volume of 9,842,106 shares. The stock had previously closed at $57.19.

Analyst Ratings Changes

A number of research firms recently issued reports on TEM. Piper Sandler reiterated a "neutral" rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective for the company. Stifel Nicolaus downgraded Tempus AI from a "buy" rating to a "hold" rating and boosted their price objective for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Bank of America raised their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a report on Friday, December 13th. Finally, Loop Capital lowered their price target on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $56.36.

Tempus AI Stock Performance

The firm has a fifty day simple moving average of $44.18 and a 200-day simple moving average of $48.29. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Insider Activity

In other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of the company's stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the completion of the sale, the insider now directly owns 15,218,365 shares of the company's stock, valued at $534,164,611.50. This represents a 1.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Eric P. Lefkofsky sold 82,056 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $58.21, for a total value of $4,776,479.76. Following the sale, the chief executive officer now directly owns 5,532,987 shares of the company's stock, valued at $322,075,173.27. The trade was a 1.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,037,702 shares of company stock valued at $89,449,651 in the last ninety days.

Institutional Trading of Tempus AI

Institutional investors have recently modified their holdings of the business. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the third quarter valued at $30,000. FNY Investment Advisers LLC purchased a new position in Tempus AI during the 4th quarter valued at about $67,000. Vestor Capital LLC acquired a new position in Tempus AI during the third quarter worth about $153,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $178,000. Finally, Stifel Financial Corp acquired a new stake in shares of Tempus AI in the third quarter valued at approximately $218,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.